These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 27437576)

  • 1. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
    Kojima Y; Volkmer JP; McKenna K; Civelek M; Lusis AJ; Miller CL; Direnzo D; Nanda V; Ye J; Connolly AJ; Schadt EE; Quertermous T; Betancur P; Maegdefessel L; Matic LP; Hedin U; Weissman IL; Leeper NJ
    Nature; 2016 Aug; 536(7614):86-90. PubMed ID: 27437576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Is Required for the Effect of CD47 Blockade on Efferocytosis and Atherogenesis-Brief Report.
    Mueller PA; Kojima Y; Huynh KT; Maldonado RA; Ye J; Tavori H; Pamir N; Leeper NJ; Fazio S
    Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e1-e9. PubMed ID: 34758632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of efferocytosis in atherosclerosis.
    Shu LX; Cao LL; Guo X; Wang ZB; Wang SZ
    J Mol Med (Berl); 2024 Jul; 102(7):831-840. PubMed ID: 38727748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonodynamic Therapy Promotes Efferocytosis via CD47 Down-Regulation in Advanced Atherosclerotic Plaque.
    Cao Y; Yao J; Gao W; Cao Z; Diabakte K; Wang L; Sun X; Tian Y
    Int Heart J; 2022 Jan; 63(1):131-140. PubMed ID: 35034916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Membrane-Coated Nanocarriers Targeting Plaques to Deliver Anti-CD47 Antibody for Atherosclerotic Therapy.
    Chen L; Zhou Z; Hu C; Maitz MF; Yang L; Luo R; Wang Y
    Research (Wash D C); 2022; 2022():9845459. PubMed ID: 35118420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation.
    Ye ZM; Yang S; Xia YP; Hu RT; Chen S; Li BW; Chen SL; Luo XY; Mao L; Li Y; Jin H; Qin C; Hu B
    Cell Death Dis; 2019 Feb; 10(2):138. PubMed ID: 30755588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade.
    Wang Y; Nanda V; Direnzo D; Ye J; Xiao S; Kojima Y; Howe KL; Jarr KU; Flores AM; Tsantilas P; Tsao N; Rao A; Newman AAC; Eberhard AV; Priest JR; Ruusalepp A; Pasterkamp G; Maegdefessel L; Miller CL; Lind L; Koplev S; Björkegren JLM; Owens GK; Ingelsson E; Weissman IL; Leeper NJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15818-15826. PubMed ID: 32541024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis.
    Bamezai S; Zhang Y; Kumari M; Lotfi M; Alsaigh T; Luo L; Kumar GS; Wang F; Ye J; Puri M; Manchanda R; Paluri S; Adkar SS; Kojima Y; Ingelsson A; Bell CF; Lopez NG; Fu C; Choi RB; Miller Z; Barrios L; Walsh S; Ahmad F; Maegdefessel L; Smith BR; Leeper NJ
    Nat Commun; 2024 Sep; 15(1):8034. PubMed ID: 39271657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Efferocytosis in Atherosclerosis.
    Kojima Y; Weissman IL; Leeper NJ
    Circulation; 2017 Jan; 135(5):476-489. PubMed ID: 28137963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRIM28/miR133a/CD47 axis acts as a potential therapeutic target in pancreatic necrosis by impairing efferocytosis.
    Zhu Q; Yuan C; Wang D; Tu B; Chen W; Dong X; Wu K; Tao L; Ding Y; Xiao W; Hu L; Gong W; Li Z; Lu G
    Mol Ther; 2024 Sep; 32(9):3025-3041. PubMed ID: 38872307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
    Jarr KU; Kojima Y; Weissman IL; Leeper NJ
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms.
    Tajbakhsh A; Rezaee M; Kovanen PT; Sahebkar A
    Pharmacol Ther; 2018 Aug; 188():12-25. PubMed ID: 29444453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.
    Flores AM; Hosseini-Nassab N; Jarr KU; Ye J; Zhu X; Wirka R; Koh AL; Tsantilas P; Wang Y; Nanda V; Kojima Y; Zeng Y; Lotfi M; Sinclair R; Weissman IL; Ingelsson E; Smith BR; Leeper NJ
    Nat Nanotechnol; 2020 Feb; 15(2):154-161. PubMed ID: 31988506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and consequences of efferocytosis in advanced atherosclerosis.
    Thorp E; Tabas I
    J Leukoc Biol; 2009 Nov; 86(5):1089-95. PubMed ID: 19414539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
    Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
    Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.